Loading…
← CockpitCompetitor Analysis › 688356.SS Jenkem Technology Co., Ltd. Class AOpen in the cockpit ↗

Jenkem Technology Co., Ltd. Class A688356.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum weak 21
Mkt cap
$563M
US dollars, full cap
Free float
50%
of shares outstanding
$/day
$37.6M
20-day average traded
Fwd P/E
30.2×
forward earnings
ROIC−WACC
-7.5 pp
WACC 14.5%
Hurdle
+25 pp
Req g minus delivered
Next earnings
134 days
1 Apr 2027
Close · CNYCN¥63.45
1D-2.7%
1W-19.0%
1M-27.8%
3M-22.0%
6M-29.5%
YTD-22.8%
1Y-31.6%
ATR %9.8%
52w lowhigh54.3% off high

What Jenkem Technology does

Employees: 304

Jenkem Technology at a glance

Size Jenkem Technology (688356.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $563M, the 3405th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥63.45 on 18 Nov 2026.

Performance Over six months the shares fell 29.5%, against -21.2% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 21 in its peer set.

Growth Revenue grew 51.6% over the last twelve months (peer median +1.8%); the operating margin is 11.5% (peer median 5.1%).

Valuation It trades at 30.2× forward earnings against a peer median of 11.3× (3rd most expensive of 10).

Price implies For today's price to make sense, revenue must grow about 36% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is +25 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 7.5 points below its cost of capital (14.5% WACC).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

7510012515021 May 202621 Aug 202618 Nov 2026Peer median 77688356.SS 76
Six months, rebased to 100: Jenkem Technology against the median of its 20 peers (local-currency closes).

Jenkem Technology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥375MCN¥313MCN¥222MCN¥287MCN¥403M
Revenue growth—+41%-23%-29%—
Gross profitCN¥282MCN¥182MCN¥135MCN¥217MCN¥330M
EBITDAn/aCN¥104MCN¥64.5MCN¥152MCN¥214M
Net incomeCN¥50.5MCN¥61.7MCN¥29.8MCN¥116MCN¥187M
Free cash flowCN¥117MCN¥30.2MCN¥99.9MCN¥49.3M-CN¥16.1M
Capital expenditureCN¥81.8MCN¥55.8MCN¥28.3MCN¥83.7MCN¥213M
Total debtCN¥5.56MCN¥7.12MCN¥13.6MCN¥8.81MCN¥4.64M

Quarterly statements and history in the cockpit →

Jenkem Technology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-20%0%600568ENTXALMS002393003850ZVRA4559002688361322562157603439CGEMMOREPENLABSENORES300147603222IMMX688356.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Jenkem Technology is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%+75%20×40×002393003850ZVRA455936132157603439SENORES688356.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Jenkem Technology is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-20%0%20%40%002393003850ZVRA45590026883613603439300147688356.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Jenkem Technology is the large dot.

Jenkem Technology competitors and peer comparison

How Jenkem Technology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Jenkem Technology against its 20 peers (data as of 18 Nov 2026)
Measure688356.SSPeer medianRank in peer set
1-month return-27.8%-11.4%4th lowest of 21
6-month return-29.5%-21.2%7th lowest of 21
Distance from 52-week high-54.3%-42.9%5th lowest of 21
Revenue growth (TTM)+51.6%+1.8%2nd highest of 19
Operating margin11.5%5.1%5th highest of 18
Forward P/E30.2×11.3×3rd most expensive of 10
Growth the price implies (Req g, 7 yrs)36.4%-4.0%2nd most demanding of 9
Growth delivered (Del g)+11.2%+10.4%4th highest of 9
Hurdle (Req g minus delivered)+25.2 pp-12.8 pp2nd most demanding of 9
ROIC minus cost of capital-7.5 pp-3.6 pp6th lowest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Jenkem Technology 688356.SSChina$563M-30%+52%11%30.2×36.4%+11.2%
Zhong Zhu Healthcare 600568.SSChina$562M-22%-6%-34%n/an/an/a
Entera Bio ENTXUnited States$568M+163%-100%n/an/an/an/a
Alumis ALMSUnited States$569M-80%-67%-5,375%n/an/an/a
Tianjin Lisheng Pharmaceutical 002393.SZChina$557M-24%-3%7%9.0×-5.8%+4.1%
Aclaris Therapeutics ACRSUnited States$555M-23%-59%-1,412%n/an/an/a
Boryung 003850.KSSouth Korea$554M-13%+6%6%11.3×-3.1%+12.6%
Zevra Therapeutics ZVRAUnited States$552M-9%+75%31%11.3×-4.9%+51.6%
Zeria Pharmaceutical 4559.TJapan$552M-12%+12%15%9.6×-12.3%+11.1%
Jinhe Biotechnology 002688.SZChina$550M-19%+7%5%8.9×1.0%+9.7%
Beijing Tong Ren Tang Chinese Medicine 3613.HKHong Kong$577M-26%-21%32%10.2×-15.4%+2.8%
Abbisko Cayman 2256.HKHong Kong$578M-39%-83%-520%n/an/an/a
Oneness Biotech 4743.TWOTaiwan$580M-13%+19%-589%n/an/an/a
Lepu Biopharma 2157.HKHong Kong$580M-43%+47%7%53.6×n/an/a
GuiZhou SanLi Pharmaceutical 603439.SSChina$583M-20%-6%5%26.8×20.9%+21.9%
Cullinan Therapeutics CGEMUnited States$585M-37%n/an/an/an/an/a
Morepen Laboratories MOREPENLAB.NSIndia$542M+121%+30%11%n/an/an/a
Senores Pharmaceuticals SENORES.NSIndia$538M+3%+40%24%32.2×n/an/a
Xiangxue Pharmaceutical 300147.SZChina$591M-41%+3%-39%n/a50.4%-12.3%
Chimin Health Management 603222.SSChina$533M-31%+1%-28%n/an/an/a
Immix Biopharma IMMXUnited States$596M-20%n/an/an/an/an/a

Questions

Which companies are Jenkem Technology's closest peers?
The cockpit's peer set: Zhong Zhu Healthcare (600568.SS), Entera Bio (ENTX), Alumis (ALMS), Tianjin Lisheng Pharmaceutical (002393.SZ), Aclaris Therapeutics (ACRS), Boryung (003850.KS), Zevra Therapeutics (ZVRA), Zeria Pharmaceutical (4559.T).
Is Jenkem Technology expensive compared with its peers?
On forward p/e it trades at 30.2× against a peer median of 11.3×, 3rd most expensive of 10 in its peer set. For today's price to make sense, revenue must grow about 36% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is +25 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Jenkem Technology stock performed?
Over six months to 18 Nov 2026 the shares returned -29.5% against -21.2% for the median peer; over one year -31.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.